Related Experiment Video
Updated: Aug 5, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma
Farideh A Javid1, Marin Golčić2, Anja Harej Hrkać3
1Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Abstract:
Despite advances in targeted and immunotherapy for melanoma, resistance to treatment and severe adverse effects pose significant challenges. This necessitates the development of new treatment strategies, and cannabinoids, because of the extensive preclinical evidence for their cytotoxic action on carcinoma cells in a variety of cancers, can offer a novel therapeutic option when used appropriately. Indeed, the potential therapeutic benefits of cannabinoids were formally recognized in the world and much more recently in the United Kingdom when cannabis-based medicinal products were moved from Schedule 1 of the Misuse of Drugs Regulations 2001 to Schedule 2 in 2018. This move further encouraged scientists to look at more applications of cannabinoids in different disorders. Although the potential psychoactivity of cannabis as a Schedule 1 drug hinders research, more research could focus on non-psychoactive components such as cannabidiol (CBD) and cannabigerol (CBG). This review summarizes some past and current research on the relationship between the cannabinoid system and the microbiome in patients with metastatic melanoma who undergo immunotherapy. The review also provides a comprehensive background on the function of the cannabinoid system in normal and diseased skin, as well as future directions in using cannabinoids as an adjunct to chemotherapeutics in the treatment of the disease.
Insights
Cannabinoids show potential as a novel melanoma treatment, offering a new therapeutic option alongside immunotherapy. Research is exploring non-psychoactive compounds like cannabidiol (CBD) and cannabigerol (CBG) for cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Microbiology
Background:
- Melanoma treatment faces challenges with drug resistance and adverse effects from current therapies.
- Cannabinoids exhibit preclinical evidence of cytotoxic effects on various cancer cells.
- Regulatory changes in the UK (2018) reclassified cannabis-based products, stimulating further research.
Purpose of the Study:
- To review the relationship between the cannabinoid system and the microbiome in metastatic melanoma patients undergoing immunotherapy.
- To provide background on cannabinoid system function in healthy and diseased skin.
- To explore future directions for cannabinoids as an adjunct cancer therapy.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of research on the endocannabinoid system's role in skin cancer.
- Examination of the interplay between cannabinoids and the microbiome.
Main Results:
- Extensive preclinical data suggests cannabinoids possess anti-cancer properties.
- The cannabinoid system plays a role in both normal skin physiology and melanoma.
- The microbiome's interaction with cannabinoids in melanoma is an emerging area of research.
Conclusions:
- Cannabinoids, particularly non-psychoactive compounds like CBD and CBG, represent a promising avenue for melanoma treatment.
- Further research is warranted to investigate cannabinoids as an adjunct therapy to enhance immunotherapy and chemotherapy efficacy.
- Understanding the cannabinoid-microbiome axis may unlock novel therapeutic strategies for melanoma.
Related Concept Videos
The Skin Microbiota
The Tumor Microenvironment
The Tumor Microenvironment
Introduction to the Human Microbiota
The Oral Microbiota
Microbiota of the Large Intestine
